AngioDynamics Promotes William Appling to Senior Vice President of Research and Development

AngioDynamics (NASDAQ:ANGO), a leading provider of innovative medical devices used by interventional radiologists and surgeons for the minimally invasive treatment of cancer and peripheral vascular disease, announced today that it has promoted its vice president of research, William Appling, 44, to the position of senior vice president of research and development, effective immediately.

In his new role, Mr. Appling will lead the continued development of the entire portfolio of AngioDynamics’ products, including the NeverTouch™ VenaCure® procedure kit and the Profiler Balloon Catheter product lines. Mr. Appling will also continue to oversee AngioDynamics’ IP portfolio that includes more than 135 issued US patents, foreign counterparts, 53 pending applications, and more than 80 issued and pending trademarks. He will also continue to head the Company’s due diligence evaluations of outside technology acquisition opportunities. Mr. Appling will remain a member of the corporate executive management team, reporting directly to Robert D. Mitchell, executive vice president and chief operating officer.

Prior to this promotion, Mr. Appling had served as the Company’s vice president of research since 2002. Mr. Appling was the vice president of product development at AngioDynamics from 1997 until 2002 and joined the Company as the manager of catheter operations when AngioDynamics was a division of E-Z-EM, Inc. in 1988.

“With his wealth of experience and proven track record, Bill has brought a tremendous level of industry expertise and leadership to AngioDynamics over the past two decades,” said Robert Mitchell, AngioDynamics’ chief operating officer. "Bill has played an instrumental role in our ability to quickly commercialize products in our R&D pipeline, allowing the Company to strategically respond to rapid changes in the market. His promotion should strengthen our research and development abilities, and his commitment to our technology, combined with his skill set, should have a significant impact on our worldwide operations. We look forward to his continued contributions."

Mr. Appling has more than 20 years of experience with research, development, and the manufacture of medical devices. Prior to joining AngioDynamics, Mr. Appling held the roles of manager of product development and manager of catheter operations at E-Z-EM, Inc.

Before this, Mr. Appling was a product development engineer for Glen Falls, NY based NAMIC Incorporated. Mr. Appling began his career in the medical device industry with roles at American Edwards Labs and Sheridan Catheter Corporation.

About AngioDynamics

AngioDynamics, Inc. is a leading provider of innovative medical devices used by interventional radiologists, surgeons, and other physicians for the minimally invasive treatment of cancer and peripheral vascular disease. The Company's diverse product line includes market-leading radiofrequency ablation systems, vascular access products, angiographic products and accessories, dialysis products, angioplasty products, drainage products, thrombolytic products, embolization products and venous products.

Safe Harbor

The statements made in this document contain certain forward-looking statements that involve a number of risks and uncertainties. Words such as "expects," "intends," "anticipates," "plans," "believes," "seeks," "estimates," or variations of such words and similar expressions, are intended to identify such forward-looking statements. Investors are cautioned that actual events or results may differ from the Company's expectations. In addition to the matters described above, the ability of the Company to develop its products, future actions by the FDA or other regulatory agencies, results of pending or future clinical trials, overall economic conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, as well as the risk factors listed from time to time in the SEC filings of AngioDynamics, Inc., including but not limited to its Annual Report on Form 10-K for the year ended June 3, 2006, may affect the actual results achieved by the Company.